{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=60", "query": { "condition": "Cancer", "page": 60 }, "page_size": 10 }, "pagination": { "page": 60, "page_size": 10, "total_count": 50362, "total_pages": 5037, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=61&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=59&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T10:43:04.657Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03637491", "title": "A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2018-08-15", "completion_date": "2021-02-02", "has_results": true, "last_update_posted_date": "2022-01-26", "last_synced_at": "2026-10-31T10:43:04.657Z", "location_count": 11, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03637491" }, { "nct_id": "NCT03112590", "title": "Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Cancer, Male", "Breast Cancer Female", "HER2-positive Breast Cancer" ], "interventions": [ { "name": "Interferon-gamma (IFN-γ)", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "OTHER" }, { "name": "Post Therapy Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2017-06-23", "completion_date": "2023-02-20", "has_results": true, "last_update_posted_date": "2023-04-19", "last_synced_at": "2026-10-31T10:43:04.657Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03112590" }, { "nct_id": "NCT00322790", "title": "Differences in Trends Malignant Germ Cell Tumors in Males and Females: A SEER Population-based Study", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "New Mexico Cancer Research Alliance", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": "2006-01", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2015-04-03", "last_synced_at": "2026-10-31T10:43:04.657Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00322790" }, { "nct_id": "NCT05798897", "title": "Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma, Adult", "Non-Hodgkin Lymphoma, Refractory", "Non-Hodgkin Lymphoma, Relapsed", "Non Hodgkin Lymphoma", "Hodgkin Lymphoma", "Hodgkin Lymphoma, Adult", "Hodgkin's Lymphoma, Relapsed, Adult" ], "interventions": [ { "name": "MT-601", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marker Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 79, "start_date": "2023-01-02", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-31T10:43:04.657Z", "location_count": 7, "location_summary": "Duarte, California • Aurora, Colorado • Denver, Colorado + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05798897" }, { "nct_id": "NCT05503797", "title": "A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer Harboring BRAF Alterations", "HGG", "LGG", "Solid Tumors" ], "interventions": [ { "name": "Plixorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fore Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": null, "sex": "ALL", "summary": "8 Years and older" }, "enrollment_count": 254, "start_date": "2023-02-21", "completion_date": "2028-12-28", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-31T10:43:04.657Z", "location_count": 30, "location_summary": "Beverly Hills, California • San Francisco, California • Westwood, Los Angeles, California + 23 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Westwood, Los Angeles", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05503797" }, { "nct_id": "NCT04003610", "title": "Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Urothelial Carcinoma", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Pemigatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2020-05-14", "completion_date": "2021-04-18", "has_results": true, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-10-31T10:43:04.657Z", "location_count": 13, "location_summary": "Greenbrae, California • Newark, Delaware • Marietta, Georgia + 10 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04003610" }, { "nct_id": "NCT00248560", "title": "Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 36, "start_date": "2005-01", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-10-31T10:43:04.657Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00248560" }, { "nct_id": "NCT07359820", "title": "A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "FGFR2 Gene Fusion/Rearrangement", "Other Solid Tumors, Adult" ], "interventions": [ { "name": "Lirafugratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elevar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-06-04", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-31T10:43:04.657Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07359820" }, { "nct_id": "NCT00665782", "title": "Measuring Stress in Women With Newly Diagnosed Stage I, Stage II, or Stage III Breast Cancer or Ductal Carcinoma In Situ of the Breast", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anxiety Disorder", "Breast Cancer", "Depression", "Psychosocial Effects of Cancer and Its Treatment" ], "interventions": [ { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "study of socioeconomic and demographic variables", "type": "OTHER" }, { "name": "assessment of therapy complications", "type": "PROCEDURE" }, { "name": "psychosocial assessment and care", "type": "PROCEDURE" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 24, "start_date": "2008-03", "completion_date": "2010-07", "has_results": false, "last_update_posted_date": "2018-07-03", "last_synced_at": "2026-10-31T10:43:04.657Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00665782" }, { "nct_id": "NCT05268224", "title": "A Tear-based, Lab-developed Test for Breast Cancer for Women With Dense Breast Tissue", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer Screening" ], "interventions": [ { "name": "Schirmer Strip", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Namida Lab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "18 Years to 100 Years · Female only" }, "enrollment_count": 1500, "start_date": "2021-10-01", "completion_date": "2024-10", "has_results": false, "last_update_posted_date": "2023-12-11", "last_synced_at": "2026-10-31T10:43:04.657Z", "location_count": 1, "location_summary": "Fayetteville, Arkansas", "locations": [ { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05268224" } ] }